1. Home
  2. LAES vs CLLS Comparison

LAES vs CLLS Comparison

Compare LAES & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEALSQ Corp

LAES

SEALSQ Corp

N/A

Current Price

$1.47

Market Cap

368.9M

Sector

Technology

ML Signal

N/A

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$1.12

Market Cap

394.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LAES
CLLS
Founded
2022
1999
Country
Switzerland
France
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
368.9M
394.4M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
LAES
CLLS
Price
$1.47
$1.12
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
★ $5.88
$4.83
AVG Volume (30 Days)
★ 3.6M
98.3K
Earning Date
09-11-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$59.43
N/A
Revenue Next Year
$41.92
$10.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$0.88
52 Week High
$7.26
$5.45

Technical Indicators

Market Signals
Indicator
LAES
CLLS
Relative Strength Index (RSI) 24.30 38.78
Support Level N/A $0.88
Resistance Level $2.56 $2.99
Average True Range (ATR) 0.11 0.10
MACD -0.02 0.07
Stochastic Oscillator 7.76 57.67

Price Performance

Historical Comparison
LAES
CLLS

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: